Tej-Preet Singh, MD
Neurology · Massapequa, NYNPI 1194798280
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,501 of the $14,186 with a category attached, or 88.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,018 and has fallen 55.6% since, to $1,339 in 2025.
Across 727 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Keystone Dental Inc.$1K
- UCB, Inc.$760
- Biogen$721
- Eisai Inc.$709
- Avanir Pharmaceuticals, Inc.$544
- plus $8K from 54 others
What the payments were for
- Speaking & faculty fees$1601%
- Food & beverage$12,50188%
- Education$1111%
- Entertainment$1,41310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,186 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $386,359 |
| OxycontinOxycodone Hcl | 45 | $85,646 |
| NuedextaDextromethorphan Hbr/Quinidine | 24 | $76,908 |
| NamzaricMemantine Hcl/Donepezil Hcl | 63 | $74,448 |
| Nurtec OdtRimegepant Sulfate | 39 | $68,863 |
| Oxtellar XrOxcarbazepine | 13 | $28,340 |
| Nucynta ErTapentadol Hcl | 15 | $23,561 |
| NeuproRotigotine | 15 | $17,815 |
| RytaryCarbidopa/Levodopa | 11 | $12,458 |
| Xtampza ErOxycodone Myristate | 11 | $12,105 |
| Trokendi XrTopiramate | 12 | $10,859 |
| Topiramate ErTopiramate | 12 | $9,204 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,758 |
| Memantine Hcl ErMemantine Hcl | 43 | $7,600 |
| Hydromorphone ErHydromorphone Hcl | 11 | $6,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt, Dilantin | $283 | $458,93666 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $544 | $76,90824 claims |
| AbbVieNamzaric | $1,925 | $74,44863 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr, Trokendi Xr | $279 | $39,20025 claims |
| Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er | $112 | $35,66626 claims |
| UCB, Inc.Neupro | $760 | $17,81515 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $413 | $13,22926 claims |
| Almatica Pharma LLCSertraline Hcl | $76 | $68358 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.
Other neurology in Massapequa
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.